Ifosfamide--pharmacologic overview.
Gisele Sarosy
Abstract
Gisele Sarosy
Abstract
Ifosfamide and its structural analogue cyclophosphamide are oxazaphosphorine nitrogen mustards, a group of compounds synthesized in West Germany more than 20 years ago. Whereas both chloroethyl groups of cyclophosphamide are attached to the same exocyclic nitrogen, one of ifosfamide's chloroethyl groups is attached to an endocyclic nitrogen. This minor structural change may account for the different pharmacologic behavior of these two compounds as well as their different spectrums of clinical activity and toxicity. Initial clinical trials of ifosfamide explored the use of a single intravenous dose. Hemorrhagic cystitis appeared to be dose-dependent and limited the use of this agent. However, the development of a systemic thiol uroprotector, such as mesna, has overcome this toxicity, permitting higher ifosfamide doses to be administered. Currently, ifosfamide is usually administered daily for five days in combination with mesna. The pharmacology and metabolism of ifosfamide may explain the toxicities associated with this compound and should be considered when designing schedules of administration.
OpenAlex reports 48 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Ifosfamide and its structural analogue cyclophosphamide are oxazaphosphorine nitrogen mustards, a group of compounds synthesized in West Germany more than 20 years ago. Whereas both chloroethyl groups of cyclophosphamide are attached to the same exocyclic nitrogen, one of ifosfamide's chloroethyl groups is attached to an endocyclic nitrogen. This minor structural change may account for the different pharmacologic behavior of these two compounds as well as their different spectrums of clinical activity and toxicity. Initial clinical trials of ifosfamide explored the use of a single intravenous dose. Hemorrhagic cystitis appeared to be dose-dependent and limited the use of this agent. However, the development of a systemic thiol uroprotector, such as mesna, has overcome this toxicity, permitting higher ifosfamide doses to be administered. Currently, ifosfamide is usually administered daily for five days in combination with mesna. The pharmacology and metabolism of ifosfamide may explain the toxicities associated with this compound and should be considered when designing schedules of administration.
Key concepts: Ifosfamide, Mesna, Nitrogen mustard, Medicine, Toxicity, Pharmacology, Cyclophosphamide, Chemotherapy